Can you get graft-versus-host disease with autologous stem cell transplant?
Despite occurring in up to 50% of patients undergoing allogeneic HSCT, the incidence of graft-versus-host disease (GVHD) after autologous HSCT is reportedly only 5-20%.
What is acute graft-versus-host disease?
Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen.
What type of reaction is graft-versus-host disease?
Graft-versus-host disease (GVHD) is an immune condition that occurs after transplant procedures when immune cells from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues; the disease is a side effect that is common after an allogeneic bone marrow transplant (stem cell transplant).
Is graft vs host disease fatal?
GVHD is a serious and potentially life-threatening condition in which the donor cells attack the recipient’s healthy cells, causing a range of medical problems.
What are the stages of GVHD?
Table 7. Staging of Acute Graft-Versus-Host Disease (GVHD) a
| Stage | Skin | GI/Gut (stool output per day)c |
|---|---|---|
| Adult | ||
| 1 | Maculopapular rash <25% BSA | 500–999 mLd or 3–4 episodes/day |
| 2 | Maculopapular rash 25%–50% BSA | 1,000–1,500 mL or 5–7 episodes/day |
| 3 | Maculopapular rash >50% BSA | >1,500 mL or >7 episodes/day |
Are on immunosuppressive therapy for graft-versus-host disease?
Moderate to severe chronic graft-versus-host disease (GVHD) is treated with potent immunosuppressive therapy (IST) to modulate the allo-immune response, control symptoms, and prevent further organ damage.
How many people survive GVHD?
Chronic graft-v-host disease (chronic GVHD) is a frequent cause of late morbidity and death after bone marrow transplantation (BMT). The actuarial survival after onset of chronic GVHD in 85 patients was 42% (95%Cl = 29%, 54%) at 10 years.
What is life expectancy after bone marrow transplant?
Although only 62% of patients survived the first year post-BMT, 98.5% of patients alive after 6 years survived at least another year. Almost 1/3 (31%) of the deaths in long-term survivors resulted from causes unrelated to transplantation or relapse.
Is there such a thing as graft versus host disease?
Abstract Graft-versus-host disease (GVHD) is a common complication of allogeneic stem cell transplantation (allo-SCT). However, a similar syndrome has been reported in autologous stem cell transplantation (ASCT) as well.
Are there any autologous stem cell transplants that are graft versus host?
Graft-versus-host disease (GVHD) is a common complication of allogeneic stem cell transplantation (allo-SCT). However, a similar syndrome has been reported in autologous stem cell transplantation (ASCT) as well. The target organs of GVHD in ASCT are the skin, liver and gastrointestinal (GI) tract, which are consistent with those in allo-SCT.
Is there such a thing as autologous GVHD?
GVHD that occurs after allo-SCT is attributable to the recognition of donor T cells or natural killer cells by recipient alloantigens. However, a similar syndrome has been reported in autologous stem cell transplantation (ASCT), without induction of an alloresponse, as a form of ‘auto-aggression’ syndrome or autologous GVHD (auto-GVHD) (1).
Is there genetic disparity in auto-GVHD?
Although there is no genetic disparity in GVHD development among patients undergoing ASCT, auto-GVHD has been reported to arise either spontaneously (2-5) or in patients receiving immunologic modulation (6,7). Auto-GVHD is generally self-limited and often requires no treatment (8-10).